Eversana has purchased HVH Precision Analytics, bringing on its analytics platform to the company’s offerings for the life-sciences industries. Originally designed for military and intelligence applications, the platform has been tailored for use in the healthcare sector.
Previously owned by Havas Health & You and Perspecta, HVH Precision Health appealed to Eversana because of its life-science experience and analytics capabilities, according to Brigham Hyde, president of Eversana’s Data and Analytics business unit.
“Their prediction-based platform is the most robust in the industry, and well known for its expertise in rare disease,” Hyde told Outsourcing-Pharma. “It has the ability to bring together millions of data sources to provide tremendous insights to our clients and their patients on different conditions to ultimately help inform treatment options.”
The ability to rapidly and effectively analyze health data collected from a variety of sources is important, Hyde added, especially as adoption of artificial intelligence (AI), machine learning (ML) and other advanced technologies becomes more widespread.
“Most AI and ML platform solutions are disjointed from the services and interfaces that create meaningful impact for patients. By providing a prediction platform, built on integrated patient data, combined with our best-in-class patient engagement solutions, commercial services, market access, and distribution, we have the ability to make predictions and take actions within the same organization and deliver value to stakeholder,” Hyde said.
According to Steve Costalas, CEO of HVH Precision Analytics, robust data and analytics technology are sorely needed in the pharmaceutical industry.
“Our technology and talented team are at the forefront of the industry and are already propelling faster analysis and actions for EVERSANA clients. The fit is seamless, and we are onboarding new programs right now,” he said.
HVH Precision Analytics reportedly will transition to the Eversana brand in the coming quarter, and the company’s leadership team will report to Hyde. Financial details of the transaction were not disclosed.